在阿尔茨海默氏病中,APP反感性寡核酸减少了粉样β聚合,并拯救了内分泌体功能障碍
Christy Hung1,2, Emre Fertan3, Frederick J Livesey2
1Human Stem Cells and Neurodegeneration Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Brain : a journal of neurology
|March 25, 2024
概括
在阿尔茨海默病模型中,针对APP基因的反意义寡核酸有效地减少了粉样β聚合物和细胞功能障碍. 这种方法为APP重复和与唐氏综合征相关的阿尔茨海默病提供了潜在的治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 阿尔茨海默病 (AD) 的发病与粉样蛋白前体蛋白 (APP) 基因剂量有关.
- APP位点的基因组重复导致自体主导早期发病的AD.
- 患有唐氏综合征 (三症组 21) 的个体由于 APP 基因的三个副本而发展出 AD.
研究的目的:
- 作为一种治疗策略来降低APP水平,研究反感性寡核酸 (ASOs).
- 评估针对APP的ASO在拯救AD模型中神经元功能障碍的有效性.
- 评估APP ASOs对粉样β聚合物形成的影响.
主要方法:
- 利用了从APP重复和三体变异21模型中获得的人类诱导多能干细胞 (hiPSC) 的皮质神经元.
- 用于针对APP基因的反意义寡核酸 (ASO) 的药物.
- 采用超敏感单聚合物成像技术来量化粉样β聚合物.
主要成果:
- 针对APP的ASOs成功地降低了APP蛋白质水平.
- 在hiPSC衍生的神经元中,ASO治疗挽救了内分泌体和自功能障碍.
- 观察到细胞内和细胞外粉样β聚合物的显著减少.
结论:
- 针对APP的ASO显示出潜在的治疗策略,用于APP基因重复引起的AD.
- 这种方法适用于单一的AD和与唐氏综合征相关的AD.
- 通过ASOs恢复生理APP水平提供了一个有希望的治疗途径,而不会影响APP功能.
相关概念视频
Alzheimer's Disease: Treatment
184
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
184
siRNA - Small Interfering RNAs
16.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.8K
Alzheimer's Disease: Overview
469
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
469


